Tyme Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Copyright West LLC. Minimum 15 minutes delayed.
September 18, 2018
September 5, 2018
August 27, 2018
September 5, 2018 at 4:15 PM EDT
August 9, 2018 at 12:30 PM EDT
April 9, 2018 at 7:45 AM EDT